Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Author:
Publish date:

Acorda Therapeutics(ACOR) - Get Report
Ampyra net revenue in the first quarter totaled $112 million, short of the $121 million consensus

Alexion Pharmaceuticals(ALXN) - Get Report
First-quarter adjusted EPS of $1.38 topped consensus of $1.24 with total revenue of $870 million

Astrazeneca(AZN) - Get Report
Results of its closely watched cancer immunotherapy study should be released by "mid-2017"

Bristol-Myers Squibb(BMY) - Get Report
Opdivo sales of $1.13 billion topped consensus of $1.03 billion

Alkermes(ALKS) - Get Report
Revenue of $192 million missed a consensus of $196 million

Celgene(CELG) - Get Report

Revlimid sales of $1.88 billion were essentially in line with consensus of $1.87 billion

Read Full Article: Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

This article was written by a staff member of TheStreet.